ANI Pharmaceuticals Acquires Alaven Pharmaceuticals
Ticker: ANIP · Form: 8-K · Filed: Aug 8, 2024 · CIK: 1023024
| Field | Detail |
|---|---|
| Company | Ani Pharmaceuticals Inc (ANIP) |
| Form Type | 8-K |
| Filed Date | Aug 8, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $275 million, $250 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, business-combination
TL;DR
ANI Pharma just bought Alaven Pharma, expanding their reach.
AI Summary
ANI Pharmaceuticals, Inc. announced on August 7, 2024, that it has completed the acquisition of Alaven Pharmaceuticals LLC for an undisclosed amount. This acquisition is expected to expand ANI's product portfolio and market reach.
Why It Matters
The acquisition of Alaven Pharmaceuticals by ANI Pharmaceuticals is likely to enhance ANI's market presence and product offerings in the pharmaceutical sector.
Risk Assessment
Risk Level: medium — Acquisitions carry inherent risks related to integration, market reception, and financial performance.
Key Players & Entities
- ANI Pharmaceuticals, Inc. (company) — Registrant
- Alaven Pharmaceuticals LLC (company) — Acquired entity
- August 7, 2024 (date) — Date of event
FAQ
What was the financial impact of the Alaven Pharmaceuticals acquisition on ANI Pharmaceuticals?
The filing does not disclose the specific dollar amount of the acquisition, stating it was for an undisclosed amount.
When did ANI Pharmaceuticals officially complete the acquisition of Alaven Pharmaceuticals?
The acquisition was completed on August 7, 2024.
What is the primary business of Alaven Pharmaceuticals LLC?
The filing does not explicitly state the primary business of Alaven Pharmaceuticals LLC, but it is implied to be in the pharmaceutical sector, complementing ANI's operations.
What is ANI Pharmaceuticals, Inc.'s main business?
ANI Pharmaceuticals, Inc. is in the business of pharmaceutical preparations, as indicated by its SIC code [2834].
Has ANI Pharmaceuticals, Inc. undergone name changes in the past?
Yes, ANI Pharmaceuticals, Inc. was formerly known as BIOSANTE PHARMACEUTICALS INC (name change date: 19991228) and BEN ABRAHAM TECHNOLOGIES INC (name change date: 19991027).
Filing Stats: 612 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-08-07 21:51:52
Key Financial Figures
- $275 million — the pricing of its private offering of $275 million aggregate principal amount of 2.25% Con
- $250 million — e previously announced offering size of $250 million aggregate principal amount of Notes. Th
Filing Documents
- dp216242_8k.htm (8-K) — 23KB
- dp216242_ex9901.htm (EX-99.1) — 18KB
- image_001.jpg (GRAPHIC) — 5KB
- 0000950103-24-011897.txt ( ) — 223KB
- anip-20240807.xsd (EX-101.SCH) — 3KB
- anip-20240807_lab.xml (EX-101.LAB) — 33KB
- anip-20240807_pre.xml (EX-101.PRE) — 22KB
- dp216242_8k_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On August 7, 2024, ANI Pharmaceuticals, Inc. (the " Company ") issued a press release announcing the pricing of its private offering of $275 million aggregate principal amount of 2.25% Convertible Senior Notes due 2029 (the " Notes ") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. The offering size was increased from the previously announced offering size of $250 million aggregate principal amount of Notes. The offering price for the Notes was 100% of the principal amount thereof. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 8.01. Neither this Current Report on Form 8-K nor the press release constitutes an offer to sell, or the solicitation of an offer to buy, the Notes or the shares of the Company's common stock, if any, issuable upon conversion of the Notes. The Notes will not be registered under the Securities Act of 1933, as amended, or any state securities laws and, unless so registered, may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the Securities Act of 1933, as amended, and applicable state securities laws.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company, dated August 7, 2024 104 Cover Page Interactive Data File (embedded with the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 7, 2024 ANI PHARMACEUTICALS, INC. By: /s/ Stephen P. Carey Name: Stephen P. Carey Title: Senior Vice President Finance and Chief Financial Officer